The use of sulfanilamide in the treatment of pneumonia has not been sufficiently encouraging to warrant recommendation of this product to replace specific antiserum. While sulfanilamide has value, the results are not striking. The fact, however, that this chemotherapeutic agent does possess some value in infections due to pneumonia led to the investigations of derivatives of sulfanilamide with a view of obtaining one which might have a more definite chemotherapeutic effect. Early this year English workers announced that the pyridine derivative of sulfanilamide described as 2-(p-aminobenzenesulfonamide)-pyridine (NH2-C6H4SO2-NHC5H4N), or sulfanilamide-pyridine, had been found to protect mice against pneumonia invasion to a much greater extent than was possible with sulfanilamide. The drug is patented and marketed in Great Britain by May & Baker under the nondescriptive name of M & B 693,1 or "Dagenan." Merck & Co. Inc.,
Current Comment. JAMA. 1938;111(23):2122. doi:10.1001/jama.1938.02790490052017
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: